1. Home
  2. SMJF vs IMMP Comparison

SMJF vs IMMP Comparison

Compare SMJF & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SMJF

SMJ International Holdings Inc. Class A Ordinary Shares

N/A

Current Price

$5.24

Market Cap

88.7M

Sector

N/A

ML Signal

N/A

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.41

Market Cap

76.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMJF
IMMP
Founded
1988
1987
Country
Singapore
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
88.7M
76.6M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
SMJF
IMMP
Price
$5.24
$0.41
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$5.50
AVG Volume (30 Days)
605.1K
899.4K
Earning Date
09-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$445.09
Revenue Next Year
N/A
N/A
P/E Ratio
$68.08
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$0.29
52 Week High
$5.70
$3.53

Technical Indicators

Market Signals
Indicator
SMJF
IMMP
Relative Strength Index (RSI) 79.08 35.88
Support Level $4.50 $0.29
Resistance Level $5.64 $0.56
Average True Range (ATR) 0.39 0.04
MACD 0.10 0.00
Stochastic Oscillator 82.21 4.36

Price Performance

Historical Comparison
SMJF
IMMP

About SMJF SMJ International Holdings Inc. Class A Ordinary Shares

SMJ International Holdings Inc specializes in the sale and distribution of a wide range of flooring products such as carpet tiles, broadloom carpets and vinyl tiles. The company operates under the proprietary brand 'SMJ'.The company also supplies environmentally friendly flooring products, promoting sustainable building practices in Asia. It has presence in several countries including Malaysia, Indonesia, Philippines, Hong Kong, PRC, Taiwan, Korea, Thailand, Vietnam, Brunei, and India. It generates revenue mainly through the sale and distribution of its flooring products prominently in Singapore.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: